Located in Franklin, Tennessee, BioMimetic Therapeutics, LLC., specialized in the development and commercialization of products to promote the healing of musculoskeletal injuries and diseases, including therapies for orthopedic and sports medicine applications.
www.biomimetics.com
The Company’s initial focus in orthopedics is the development of Augment® Bone Graft (rhPDGF/Beta-TCP) as a substitute for autograft in foot and ankle fusions. All Augment branded products are based upon recombinant human platelet-derived growth factor (rhPDGF-BB), which is a bioengineered form of PDGF, one of the body’s principal agents to stimulate and direct healing and regeneration.
